You are here
Generic Version of Brethine Approved
Terbutaline Sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema, and is the generic equivalent of Brethine(R) Tablets marketed by Novartis Pharmaceuticals and aaiPharma Inc.
"We are pleased that our product development efforts are beginning to pay dividends with our first product approval thus far in 2005," said Arthur Bedrosian, president of Lannett. "With ten product applications currently pending at the FDA, we look forward to additional approvals this year, further building our product offering."
According to NDC Health, the total U.S. market for Terbutaline Sulfate tablets is approximately $11 million. Currently, there is only one other generic supplier marketing this product.
Source: Lannett Company, Inc.